Prev Close | 6.66 |
Open | 6.70 |
Day Low/High | 6.08 / 6.80 |
52 Wk Low/High | 4.22 / 8.81 |
Volume | 1.58M |
Prev Close | 6.66 |
Open | 6.70 |
Day Low/High | 6.08 / 6.80 |
52 Wk Low/High | 4.22 / 8.81 |
Volume | 1.58M |
Exchange | NASDAQ |
Shares Outstanding | 90.25B |
Market Cap | 619.10M |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.
The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.
The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.
Until market conditions shift, I won't be making any sizable buys.
The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
This small-cap company's shares are half where they ended 2015.
Don't trade the headline numbers, but cash in on those traders that do.